Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044408 · ClinicalTrials.gov registry record · Phase 3
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
A Phase 3 study, sponsored by Chromaderm.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT00044408 is a Phase 3 study that has completed, run by Chromaderm. The registered enrollment target is 200 participants.
The verdict
NCT00044408, a Phase 3 study, has completed, sponsored by Chromaderm.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
Interventions
- DRUG Ruboxistaurin mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044408
The ClinicalTrials.gov registry entry for NCT00044408 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chromaderm, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruboxistaurin mesylate is the first listed.
NCT00044408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044408 about?
NCT00044408 is a clinical study titled "Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes". The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.
What is the current status of trial NCT00044408?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2002-07. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00044408?
The interventions under investigation include: Ruboxistaurin mesylate (DRUG).
Who is sponsoring clinical trial NCT00044408?
This trial is sponsored by Chromaderm, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.